drugset
drugset / Trial / NCT06026397

A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects

NCT06026397 ↗

Phase 1 Completed 24 enrolled Guangzhou Zhiyi Biotechnology Co., Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of orally administered SK10 powders in healthy adult subjects at three dose levels, following single and multiple doses.

Timeline

Start
2023-08-01
Primary completion
2024-02-11
Completion
2024-02-11

Drugs

EvaluationDrugModalityDoseRoute
Subject SK10 Unknown — Oral

Indications

chemotherapy-induced toxicity